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Patient assessment
The patient should be made aware of the need and indication for the DLI therapy.
Patients should be consented in clinic. It is recommended that patients are appropriately restaged shortly prior to DLI therapy to enable adequate monitoring of disease response. Mixed chimerism results should be confirmed on at least two separate tests. The patient should be warned of the potential risks of DLIs which are principally those of graft-versus-host disease (incidence ca. 30% but dependent on cell dose) and graft hypoplasia (incidence 5 -10%).
Patients for DLI should be referred to BMT MDT for discussion to support planning.
Donor Lymphocyte Dosage
The evidence for DLI dosage is limited and so the following is for guidance only. Individual patient dosing should be carefully considered with the consultant, bearing in mind the potential risk and previous degree of graft-versus-host disease as well as the aggressiveness of the disease being treated. Dosing should be discussed with the BMT consultant.
After the initial dose, the timing and frequency of subsequent infusions is dependent on individual patient circumstances and should be discussed with the consultant. Standard frequency for DLI is every 3 months but can be given bimonthly in cases of urgent clinical need. Patients with CML with molecular evidence of the BCR-ABL transcript post allogeneic bone marrow transplantation OR patients with mixed chimerism following RIC bone marrow transplantation will usually receive the initial lowest dose of 1 x 10 6 CD3+ cells / kg. If necessary, subsequent doses will be escalated according to response. Patients in whom there is clinical evidence of disease resistance or progression will usually require a higher initial dose of lymphocytes. Individual dosing should be discussed with the BMT consultant.
Donor Lymphocyte Infusion
(1) The request for the donor lymphocytes should be made with NHSBT by completing the appropriate request form. Note that an additional form is required to request frozen cell issue (2) DLI schedule to be issued weekly, distribution should include appropriate administration staff to ensure an encounter is created for the day unit in order to ensure correct prescribing on EPR. Donor lymphocytes should be prescribed electronically on EPR . Ensure that the correct pre-registration encounter for the day of DLI is chosen. Prescription of DLI should be completed as for any other therapeutics by using the DLI Prescribing PowerPlan. The required dose should be selected from the pre-set doses (as above based on the escalating schedule) together with the premedication drugs. Use free text for non-conventional doses. The date and time of DLI should be changed accordingly, as the requested time for administration will automatically appear as the time of prescription. For frozen doses patients are pre-medicated with paracetamol (1 g po 30mins pre DLI) and chlorphenamine (10 mg iv bolus 30mins pre DLI). Avoid hydrocortisone. (3) Donor lymphocytes are given intravenously either peripherally or via central venous catheter as a bolus or stat infusion in the Day Treatment Unit (4) Refer to Nursing care plan N62
